French Glendon E. III 4

What Happened Glendon E. French III, President & CEO and a director of Pulmonx (LUNG), reported three dispositions totaling 56,149 shares for aggregate proceeds of about $86,874. Transactions: 4,171 shares on 2026-06-01 at $1.54 ($6,423), 38,467 shares on 2026-06-01 at $1.54 ($59,239), and 13,511 shares on 2026-06-02 at $1.57 ($21,212). The filing indicates these sales were made to cover tax withholding obligations related to vested Restricted Stock Units (RSUs).

Key Details

• Transaction dates/prices: 2026-06-01 — 4,171 & 38,467 shares at $1.54; 2026-06-02 — 13,511 shares at $1.57.
• Total shares sold: 56,149; total proceeds: ~$86,874.
• Purpose: Footnote (F1) states the shares were sold to cover tax withholding for RSU vesting.
• Related grants: filing cites RSU grants with vesting schedules (notes F2 — grant tied to Dec 1, 2025; F3 — grant tied to Jun 2, 2025; and RSUs granted Mar 1, 2023 as referenced in F1).
• Shares held by trust: some shares are held by the Glendon E French & Gayle French Trustees French Family Rev Trust (footnote F4).
• Shares owned after transaction: not specified in the provided summary; see the Form 4 for post-transaction holdings.
• Filing timeliness: Form filed 2026-06-03 for transactions on 2026-06-01 and 06-02 — appears timely under standard two-business-day reporting.

Context These sales are reported as tax-withholding dispositions related to RSU vesting (common for equity-compensated executives) and therefore are routine and not necessarily a directional signal about the CEO’s view of the company. For full details, including post-transaction holdings and original Form 4 text, consult the SEC filing (Accession No. 0001805624-26-000002).